Bacterial meningitis epidemiology and return of Neisseria meningitidis serogroup A cases in Burkina Faso in the five years following MenAfriVac mass vaccination campaign

Diallo, Alpha Oumar; Soeters, Heidi M.; Yameogo, Issaka; Sawadogo, Guetawendé; Aké, Flavien; Lingani, Clément; Wang, Xin; Bita, Andre; Fall, Amadou; Sangaré, Lassana; Ouédraogo-Traoré, Rasmata; Medah, Isaïe; Bicaba, Brice; Novak, Ryan T.

doi:10.1371/journal.pone.0187466

- Add this to...
- Twitter
- Facebook
- Google Bookmarks
- LinkedIn

Bacterial meningitis epidemiology and return of Neisseria meningitidis serogroup A cases in Burkina Faso in the five years following MenAfriVac mass vaccination campaign

Published Date:

Nov 02 2017

Publisher's site:

http://dx.doi.org/10.1371/journal.pone.0187466 New Site Icon

Source:

PLoS One. 12(11).

Language:

English

[PDF-2.95 MB]

Details:

Alternative Title:

PLoS One

Personal Author:

Diallo, Alpha Oumar ; Soeters, Heidi M. ; Yameogo, Issaka ; Sawadogo, Guetawendé ; Aké, Flavien ; ... More ▼

Corporate Authors:

for the MenAfriNet Consortium

Description:

Background

Historically, Neisseria meningitidis serogroup A (NmA) caused large meningitis epidemics in sub-Saharan Africa. In 2010, Burkina Faso became the first country to implement a national meningococcal serogroup A conjugate vaccine (MACV) campaign. We analyzed nationwide meningitis surveillance data from Burkina Faso for the 5 years following MACV introduction.

Methods

We examined Burkina Faso’s aggregate reporting and national laboratory-confirmed case-based meningitis surveillance data from 2011–2015. We calculated incidence (cases per 100,000 persons), and described reported NmA cases.

Results

In 2011–2015, Burkina Faso reported 20,389 cases of suspected meningitis. A quarter (4,503) of suspected meningitis cases with cerebrospinal fluid specimens were laboratory-confirmed as either S. pneumoniae (57%), N. meningitidis (40%), or H. influenzae (2%). Average adjusted annual national incidence of meningococcal meningitis was 3.8 (range: 2.0–10.2 annually) and was highest among infants aged <1 year (8.4). N. meningitidis serogroup W caused the majority (64%) of meningococcal meningitis among all age groups. Only six confirmed NmA cases were reported in 2011–2015. Five cases were in children who were too young (n = 2) or otherwise not vaccinated (n = 3) during the 2010 MACV mass vaccination campaign; one case had documented MACV receipt, representing the first documented MACV failure.

Conclusions

Meningococcal meningitis incidence in Burkina Faso remains relatively low following MACV introduction. However, a substantial burden remains and NmA transmission has persisted. MACV integration into routine childhood immunization programs is essential to ensure continued protection.

Subject:

[+]

Pubmed ID:

29095907

Pubmed Central ID:

PMC5667755

Document Type:

Journal Article

Collection(s):

CDC Public Access

Main Document Checksum:

[+]

Supporting Files:

	pone.0187466.nxml	text/xml
	pone.0187466.s001.xlsx	application/vnd.openxmlformats-officedocument.spreadsheetml.sheet
	pone.0187466.s002.docx	application/vnd.openxmlformats-officedocument.wordprocessingml.document
	pone.0187466.s003.docx	application/vnd.openxmlformats-officedocument.wordprocessingml.document
	pone.0187466.t001.gif	image/gif
	pone.0187466.t001.jpg	image/jpeg
	pone.0187466.t002.gif	image/gif
	pone.0187466.t002.jpg	image/jpeg
	pone.0187466.t003.gif	image/gif
	pone.0187466.t003.jpg	image/jpeg
	pone.0187466.g001.gif	image/gif
	pone.0187466.t004.gif	image/gif
	pone.0187466.t004.jpg	image/jpeg
	pone.0187466.g001.jpg	image/jpeg
	pone.0187466.g002.gif	image/gif
	pone.0187466.g002.jpg	image/jpeg
	pone.0187466.g003.gif	image/gif
	pone.0187466.g003.jpg	image/jpeg
	pone.0187466.g004.gif	image/gif
	pone.0187466.g004.jpg	image/jpeg

No Related Documents.

You May Also Like:

Phenotypic and genotypic characterization of meningococcal carriage and disease isolates in Burkina Faso after mass vaccination with a serogroup a conjugate vaccine

Personal Author:

Kristiansen, Paul A; Ba, Absatou Ky; Sanou, Idrissa; Ouédraogo, Abdoul-Salam; Ouédraogo, Rasmata; Sangaré, Lassana; Diomandé, Fabien; Kandolo, Denis; Thomas, Jennifer Dolan; Clark, Thomas A; LaForce, Marc; Caugant, Dominique A;

Published Date:

Aug 02 2013

Source:

BMC Infect Dis. 2013; 13:363.

Description:

BackgroundThe conjugate vaccine against serogroup A Neisseria meningitidis (NmA), MenAfriVac, was first introduced in mass vaccination campaigns of the 1-29-year-olds in Burkina Faso in 2010. The aim of this study was to genetically characterize meni...

File Type:

[PDF - 300.64 KB]
Persistent low carriage of serogroup A Neisseria meningitidis two years after mass vaccination with the meningococcal conjugate vaccine, MenAfriVac

Personal Author:

Kristiansen, Paul A; Ba, Absatou Ky; Ouédraogo, Abdoul-Salam; Sanou, Idrissa; Ouédraogo, Rasmata; Sangaré, Lassana; Diomandé, Fabien; Kandolo, Denis; Saga, Inger Marie; Misegades, Lara; Clark, Thomas A; Préziosi, Marie-Pierre; Caugant, Dominique A;

Published Date:

Dec 4 2014

Source:

BMC Infect Dis. 14(1).

Description:

BackgroundThe conjugate vaccine against serogroup A Neisseria meningitidis (NmA), MenAfriVac, is currently being introduced throughout the African meningitis belt. In repeated multicentre cross-sectional studies in Burkina Faso we demonstrated a sign...

File Type:

[PDF - 696.37 KB]
MenAfriNet: A Network Supporting Case-Based Meningitis Surveillance and Vaccine Evaluation in the Meningitis Belt of Africa

Personal Author:

Patel, Jaymin C.; Soeters, Heidi M.; Diallo, Alpha Oumar; Bicaba, Brice W.; Kadadé, Goumbi; Dembélé, Assétou Y.; Acyl, Mahamat A.; Nikiema, Christelle; Lingani, Clement; Hatcher, Cynthia; Acosta, Anna M.; Thomas, Jennifer D.; Diomande, Fabien; Martin, Stacey; Clark, Thomas A.; Mihigo, Richard; Hajjeh, Rana A.; Zilber, Catherine H.; Aké, Flavien; Mbaeyi, Sarah A.; Wang, Xin; Moisi, Jennifer C.; Ronveaux, Olivier; Mwenda, Jason M.; Novak, Ryan T.;

Published Date:

Oct 31 2019

Source:

J Infect Dis. 220(Suppl 4):S148-S154

Description:

Meningococcal meningitis remains a significant public health threat, especially in the African meningitis belt where Neisseria meningitidis serogroup A historically caused large-scale epidemics. With the rollout of a novel meningococcal serogroup A c...

Public Access
Available on:

October 31, 2020
Bacterial meningitis epidemiology in 5 countries in the meningitis belt of sub-Saharan Africa, 2015–2017

Personal Author:

Soeters, Heidi M.; Diallo, Alpha Oumar; Bicaba, Brice W.; Kadadé, Goumbi; Dembélé, Assétou Y.; Acyl, Mahamat A.; Nikiema, Christelle; Sadji, Adodo Yao; Poy, Alain N.; Lingani, Clement; Tall, Haoua; Sakandé, Souleymane; Tarbangdo, Félix; Aké, Flavien; Mbaeyi, Sarah A.; Moïsi, Jennifer; Paye, Marietou F.; Sanogo, Yibayiri Osee; Vuong, Jeni T.; Wang, Xin; Ronveaux, Olivier; Novak, Ryan T.;

Corporate Authors:

MenAfriNet Consortium

Published Date:

Oct 31 2019

Source:

J Infect Dis. 220(Suppl 4):S165-S174

Description:

Background:The MenAfriNet Consortium supports strategic implementation of case-based meningitis surveillance in key high-risk countries of the African meningitis belt: Burkina Faso, Chad, Mali, Niger, and Togo. We describe bacterial meningitis epidem...

Public Access
Available on:

October 31, 2020
Molecular Characterization of Invasive Meningococcal Isolates from Countries in the African Meningitis Belt before Introduction of a Serogroup A Conjugate Vaccine

Personal Author:

Caugant, Dominique A.; Kristiansen, Paul A.; Wang, Xin; Mayer, Leonard W.; Taha, Muhamed-Kheir; Ouédraogo, Rasmata; Kandolo, Denis; Bougoudogo, Flabou; Sow, Samba; Bonte, Laurence;

Published Date:

Sep 27 2012

Source:

PLoS One. 7(9).

Description:

BackgroundThe serogroup A conjugate meningococcal vaccine, MenAfriVac, was introduced in mass vaccination campaigns in December 2010 in Burkina Faso, Mali and Niger. In the coming years, vaccination will be extended to other African countries at risk...

File Type:

[PDF - 256.13 KB]